DLin-KC2-DMA (CAS No 1190197-97-7) is a lipid-based nanoparticle formulation commonly used in the field of biomedical research particularly in the delivery of nucleic acids for gene therapy and RNA interference Originating from advancements in lipid nanoparticle technology it functions by encapsulating therapeutic nucleic acids facilitating their cellular uptake and endosomal escape This enables effective delivery into target cells enhancing gene silencing or expression DLin-KC2-DMA exhibits potent activity in vitro typically in the nanomolar to low micromolar range allowing it to be a versatile tool in drug development and screening Its applications extend to various cell models including primary and immortalized cell lines as well as in vivo animal studies where it aids in the evaluation of gene delivery efficacy and safety Experimental concentrations typically depend on the specific research design to ensure optimal results within each study s context